Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The challenge is the lack of robust clinical data backing these alternatives
| Weeks | Dose | Purpose | |---|---|---| | 1 to 4 | 0.25 mg once weekly | Tolerability induction | | 5 to 8 | 0.5 mg once weekly | Minimum effective therapeutic dose | | 9 to 12 (optional) | 1.0 mg once weekly | Enhanced glycemic control | | 13 to 16 (optional) | 1.7 mg once weekly | Bridge to maximum dose | | 17+ (optional) | 2.0 mg once weekly | Maximum approved dose for T2D | Dose advancement is not mandatory at every step
For employers that dont currently cover GLP-1 drugs for weight loss, the landscape may continue to shift
New molecules and indications for GLP-1 medicines
Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats
